Latest Ratios: P/E Ratio -10.4x · EV/EBITDA N/A · ROE N/A. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $329M | $266M | $80M | $100M | $67M | $121M | $128M | $149M | $135M | $119M | $29M |
| Enterprise Value | $445M | $382M | $172M | $146M | $88M | $111M | $101M | $102M | $127M | $116M | $13M |
| P/E Ratio → | -10.40 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 46.31 | 5.28 | 3.28 | 19.60 | 99.45 | 2.38 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -227.7% | -67.2% | -50.7% | -343.6% | -245.8% | -115.7% |
| ROA | -166.6% | -166.6% | -205.9% | -166.0% | -122.9% | -85.5% | -60.1% | -46.3% | -211.1% | -162.7% | -101.6% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -174.6% | -174.6% | — | -366.1% | -186.8% | -105.9% | -67.1% | -51.1% | -336.2% | -246.0% | -115.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 11.11 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -4.05 | -1.12 | -1.04 | -1.20 | -2.56 | -1.28 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.21 | -3.21 | -7.49 | -13.71 | -36.54 | -61.43 | -268.71 | -151.80 | -40.37 | -1352.92 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.42 | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 | 5.46 | 17.10 | 4.19 | 1.29 | 4.18 |
| Quick Ratio | 2.42 | 2.42 | 0.49 | 1.77 | 1.58 | 4.63 | 5.46 | 17.10 | 4.19 | 1.29 | 4.18 |
| Cash Ratio | 2.21 | 2.21 | 0.43 | 1.64 | 1.43 | 4.39 | 5.03 | 16.84 | 3.92 | 1.03 | 4.06 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | — | — | 0.1% | 0.1% | 0.3% | 0.7% | 1.0% | 2.6% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% | 0.3% | 0.7% | 1.0% | 2.6% |
| Shares Outstanding | — | $64M | $62M | $60M | $59M | $59M | $57M | $52M | $39M | $36M | $29M |
Binary clinical trial outcome
As reported in financial statements, GALT's negative P/E of -10.40 reflects a pre-revenue entity where traditional valuation multiples are effectively meaningless, forcing investors to rely on the binary probability of clinical success rather than current earnings or cash flow generation to justify the company's market capitalization.
The absence of meaningful revenue or positive EBITDA renders standard valuation metrics like P/E or EV/EBITDA inapplicable for assessing intrinsic value. Investors should monitor the company's market cap relative to the potential addressable market for belapectin, as current pricing appears to be driven entirely by speculative sentiment regarding the NAVIGATE trial outcomes.
Based on GALT's reported figures, the current ratio has fluctuated significantly, reaching 2.15 in 2026Q1, yet this metric masks the underlying reality that the company lacks recurring revenue to sustain its operations without frequent, dilutive capital raises to fund the ongoing Phase III clinical trial requirements.
While the current ratio suggests a superficial level of short-term solvency, the rapid depletion of cash reserves indicates that liquidity is highly sensitive to the timing of clinical milestones. The volatility in the quick ratio over the last ten quarters warrants further investigation into the company's ability to manage its payables as trial-related expenses escalate.
According to recent market data, GALT's valuation and financial profile diverge sharply from commercial-stage peers like Halozyme, as the company's lack of revenue and negative ROA of -28.6% highlight its status as a high-risk, clinical-stage entity compared to more established biotechnology firms with diversified revenue streams.
The gap between GALT and its peers is structural rather than temporary, rooted in the company's single-asset focus and lack of commercial infrastructure. Investors should note that while peers may trade on earnings multiples, GALT remains tethered to the high-risk, binary nature of its clinical development pipeline.
As indicated by the company's financial disclosures, the P/B ratio is a commonly misapplied metric for GALT, as it fails to account for the fact that the company's book value is largely comprised of accumulated deficits rather than tangible assets, rendering the ratio useless for assessing true enterprise value.
Instead of relying on book value, analysts should focus on the cash runway and the net present value of the lead clinical asset. Using traditional accounting ratios for a company with no commercialized products and negative equity may lead to a fundamental misunderstanding of the firm's actual financial risk profile.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GALT stock.
Galectin Therapeutics Inc.'s current P/E ratio is -10.4x. This places it at the 50th percentile of its historical range.
Based on historical data, Galectin Therapeutics Inc. is trading at a P/E of -10.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.